查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046549

個人化醫療中的生成式人工智慧市場－全球產業規模、佔有率、趨勢、機會與預測：個人化醫療療法、部署模式、最終用戶、區域和競爭對手，2021-2031年

Generative AI in Personalized Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Personalized Medicine Therapeutics, By Deployment Model, By End-User By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球個人化醫療領域的生成式人工智慧市場預計將從 2025 年的 1.9729 億美元大幅成長至 2031 年的 7.9852 億美元，複合年成長率為 26.24%。

該領域的生成式人工智慧利用基礎模型處理複雜的基因組、表現型和臨床數據，從而促進獨特分子結構、合成患者群和個人化治療策略的開發。這一市場成長的根本驅動力在於縮短藥物研發週期的迫切需求，以及這些演算法分析非結構化多體學資料集以實現精準診斷的能力。皮斯托亞聯盟在2024年發布的報告反映了這一轉變，報告顯示，在其調查中，83%的生命科學專業人士正在使用生成式人工智慧，凸顯了該行業正積極向這些用於治療方法創新的先進計算工具轉型。

市場概覽
預測期 2027-2031
市場規模：2025年 1.9729億美元
市場規模：2031年 7.9852億美元
複合年成長率：2026-2031年 26.24%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

然而，儘管發展勢頭強勁，市場仍面臨監管碎片化和數據合規方面的重大挑戰。主要全球區域缺乏統一的法律體制，為尋求實施標準化跨境解決方案的跨國相關人員帶來了不確定性。這種缺乏統一管治，加上演算法偏差和資料隱私問題等固有風險，成為將生成式人工智慧安全、可擴展地整合到臨床工作流程中的瓶頸。

市場促進因素

全球個人化醫療領域生成式人工智慧市場的主要驅動力在於該技術能夠最佳化藥物研發流程，進而降低研發成本並縮短產品上市時間。生成式演算法正被擴大用於加速預測分子間相互作用和最佳化先導化合物，直接滿足了產業降低傳統藥物發現方法通用的高失敗率和高成本的需求。這些效率的提升正在帶來快速的經濟效益。根據英偉達於2025年7月發布的《醫療保健和生命科學領域人工智慧現狀：2025年趨勢》調查報告，45%使用生成式人工智慧的醫療保健和生命科學機構將在12個月內實現投資回報，這表明這些工具正在研究和臨床環境中快速實現價值。

除了這些營運優勢外，市場還受益於公共和私人精準醫療舉措投資的增加。創業投資和企業的資金正湧入人工智慧原生生物技術公司，這些公司正利用基礎模型來擴展個人化治療方法的開發。例如，Isomorphic Labs 於 2025 年 3 月宣布，已在其首輪外部資金籌措中籌集了 6 億美元，用於推動其人工智慧驅動的藥物發現引擎。這種對特定領域的熱情也體現在更廣泛的金融趨勢中。根據 Mintz 於 2025 年 3 月發布的一份報告，2024 年全球生物技術人工智慧公司籌集了約 56 億美元的創業投資，這表明人們對該領域變革個人化醫療的潛力充滿信心。

市場挑戰

監管碎片化和資料合規的複雜性是全球生成式人工智慧市場在個人化醫療領域發展的主要障礙。主要地區缺乏統一的法律體制，迫使跨國相關人員在相互衝突的資料隱私法律和檢驗標準所構成的混亂體系中艱難前進。這種不一致造成了巨大的不確定性，使得各組織難以部署標準化的跨境解決方案。因此，演算法偏差和數據處理相關的法律風險阻礙了投資，延緩了生成式人工智慧工具從研究機構轉化為實際臨床應用的方法。

這種不確定性的影響在專家對技術採納的看法中得到了清晰的體現。 2024年，美國醫學會（AMA）指出，近47%的醫生強調需要加強對人工智慧醫療設備的法律規範，以確保安全性和建立信任。這種對更清晰的管治的呼籲表明，當前監管的不一致正在直接導致醫療專業人員的猶豫不決。只要這些合規瓶頸持續存在，個人化醫療的擴充性就會受到限制，導致個人化治療方案的實施延遲。

市場趨勢

一個關鍵趨勢是開發特定領域的大規模生物語言模型（Bio-LLM）。這標誌著從應用通用演算法轉向使用基於海量生物資料集訓練的專用架構。與通用模型不同，這些Bio-LLM使用胺基酸序列、基因組序列和化學結構進行預訓練，從而破解生物系統的底層語法，實現更精確的標靶辨識和個人化治療方法的設計。隨著各機構追求更高的準確率，這種方法正迅速獲得認可。根據Menlo Ventures於2025年10月發布的報告《2025：醫療保健領域人工智慧現狀》，22%的醫療機構將採用特定領域的人工智慧工具，比前一年成長七倍。這表明，人們越來越傾向於使用為特定目的而建立的邏輯，而不是通用的基礎模型。

同時，用於全面患者表現型分析的多模態平台模型正在興起，它將臨床文本、醫學圖像和體學數據等多種數據流整合到一個統一的分析框架中，從而變革診斷方式。這種融合使得生成式系統能夠建構全面的病患檔案，捕捉到單模態分析中常被忽略的複雜疾病標記物，進而最佳化病患分層和個人化治療方法的選擇。業界對處理複雜視覺和診斷數據的關注度日益提高。根據英偉達 (NVIDIA) 於 2025 年 7 月發布的調查報告《醫療保健和生命科學領域的人工智慧現狀：2025 年趨勢》，71% 的醫療技術公司將醫學影像和診斷列為人工智慧的主要應用場景，這凸顯了該行業致力於利用多模態能力獲得更深入的臨床洞察。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：個人化醫療領域生成式人工智慧的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 個人化醫療（依治療方法分類，包括藥物、基因組醫學和醫療設備）
    • 部署模式（本地部署、雲端部署）
    • 依最終使用者（醫院/診所、門診手術中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美個人化醫療領域生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲個人化醫療領域生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區個人化醫療領域生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲個人化醫療領域生成式人工智慧的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲個人化醫療領域生成式人工智慧市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球個人化醫療領域生成式人工智慧市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Syntegra
  • NioyaTech
  • Saxon
  • IBM Watson
  • Microsoft Corporation
  • Google LLC
  • Tencent Holdings Ltd.
  • Neuralink Corporation
  • Johnson & Johnson
  • OpenAI
  • Oracle

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20049

The Global Generative AI in Personalized Medicine Market is anticipated to expand substantially, growing from USD 197.29 Million in 2025 to USD 798.52 Million by 2031, representing a CAGR of 26.24%. Generative AI within this sector leverages foundation models to process intricate genomic, phenotypic, and clinical data, thereby facilitating the development of unique molecular structures, synthetic patient cohorts, and tailored treatment strategies. This market growth is fundamentally driven by the urgent need to shorten pharmaceutical R&D timelines and the capacity of these algorithms to analyze unstructured multi-omics datasets for precision diagnostics. Reflecting this shift, the Pistoia Alliance reported in 2024 that 83% of life science professionals used generative AI in their research, highlighting an aggressive industry transition toward these advanced computational tools for therapeutic innovation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 197.29 Million
Market Size 2031USD 798.52 Million
CAGR 2026-203126.24%
Fastest Growing SegmentHospitals and Clinics
Largest MarketNorth America

However, despite this strong momentum, the market faces significant hurdles related to regulatory fragmentation and data compliance. The lack of consistent legal frameworks across major global regions creates uncertainty for multinational stakeholders trying to implement standardized, cross-border solutions. This absence of harmonized governance, along with inherent risks such as algorithmic bias and data privacy issues, creates a bottleneck that complicates the safe and scalable incorporation of generative AI into clinical workflows.

Market Driver

A primary engine for the Global Generative AI in Personalized Medicine Market is the reduction of pharmaceutical R&D costs and time-to-market, enabled by the technology's ability to optimize drug development processes. Generative algorithms are increasingly utilized to accelerate molecular interaction predictions and refine lead compounds, directly addressing the industry's need to lower the high attrition rates and expenses common in traditional discovery methods. These efficiencies are yielding rapid financial benefits; according to NVIDIA's 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey from July 2025, 45% of healthcare and life sciences organizations using generative AI achieved a return on investment within 12 months, demonstrating the quick value realization these tools offer in research and clinical environments.

In parallel with these operational gains, the market is heavily supported by rising investment in public and private precision medicine initiatives. Venture capital and corporate funding are flowing into AI-native biotech firms that employ foundation models to scale tailored therapeutic development. For example, Isomorphic Labs announced in March 2025 that it raised $600 million in its first external funding round to advance its AI-driven drug design engine. This targeted enthusiasm is mirrored in broader financial trends; according to Mintz in March 2025, biotechnology AI companies drew approximately $5.6 billion in global venture capital during 2024, signaling robust confidence in the sector's potential to transform personalized care.

Market Challenge

Regulatory fragmentation and data compliance complexities serve as major barriers inhibiting the growth of the Global Generative AI in Personalized Medicine Market. The lack of a unified legal structure across key regions compels multinational stakeholders to manage a confusing array of conflicting data privacy laws and validation standards. This inconsistency generates considerable uncertainty, making it difficult for organizations to deploy standardized, cross-border solutions. As a result, legal risks associated with algorithmic bias and data handling stifle investment and delay the progression of generative AI tools from research laboratories to active clinical application.

The consequences of this uncertainty are clearly reflected in professional sentiment regarding technology adoption. In 2024, the American Medical Association noted that nearly 47% of physicians stressed the need for increased regulatory oversight of AI-enabled medical devices to ensure safety and establish trust. This call for clearer governance indicates that the current lack of harmonized regulations directly causes hesitation among medical practitioners. As long as these compliance bottlenecks remain, the scalability of personalized medicine initiatives will be restricted, thereby slowing the delivery of individualized treatment protocols.

Market Trends

A significant trend is the development of Domain-Specific Biological Large Language Models (Bio-LLMs), marking a shift from adapting general-purpose algorithms to using specialized architectures trained on extensive biological datasets. Unlike generic models, these Bio-LLMs are pre-trained on amino acid sequences, genomic strings, and chemical structures, allowing them to decode the underlying syntax of biological systems for more accurate target identification and personalized therapeutic design. This approach is gaining rapid traction as organizations aim for greater precision; according to Menlo Ventures' '2025: The State of AI in Healthcare' report from October 2025, 22% of healthcare organizations have implemented domain-specific AI tools, a seven-fold increase from the previous year that signals a maturing preference for purpose-built logic over generic foundation models.

Simultaneously, the Emergence of Multi-Modal Foundation Models for Holistic Patient Phenotyping is transforming diagnostics by integrating diverse data streams, such as clinical text, medical imaging, and omics profiles, into a single analytical framework. This convergence enables generative systems to create comprehensive patient representations that capture complex disease markers often missed by unimodal analysis, thereby refining patient stratification and individualized treatment selection. The industry's focus on processing complex visual and diagnostic data is intensifying; according to NVIDIA's July 2025 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey, 71% of medical technology organizations identified medical imaging and diagnostics as a leading AI use case, highlighting the sector's commitment to leveraging multi-modal capabilities for deeper clinical insights.

Key Market Players

  • Syntegra
  • NioyaTech
  • Saxon
  • IBM Watson
  • Microsoft Corporation
  • Google LLC
  • Tencent Holdings Ltd.
  • Neuralink Corporation
  • Johnson & Johnson
  • OpenAI
  • Oracle

Report Scope

In this report, the Global Generative AI in Personalized Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics

  • Pharmaceutical
  • Genomic Medicine
  • Devices

Generative AI in Personalized Medicine Market, By Deployment Model

  • On-premises
  • Cloud Based

Generative AI in Personalized Medicine Market, By End-User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

Generative AI in Personalized Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Generative AI in Personalized Medicine Market.

Available Customizations:

Global Generative AI in Personalized Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generative AI in Personalized Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Personalized Medicine Therapeutics (Pharmaceutical, Genomic Medicine, Devices)
    • 5.2.2. By Deployment Model (On-premises, Cloud Based)
    • 5.2.3. By End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Generative AI in Personalized Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Personalized Medicine Therapeutics
    • 6.2.2. By Deployment Model
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Generative AI in Personalized Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Personalized Medicine Therapeutics
        • 6.3.1.2.2. By Deployment Model
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Generative AI in Personalized Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Personalized Medicine Therapeutics
        • 6.3.2.2.2. By Deployment Model
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Generative AI in Personalized Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Personalized Medicine Therapeutics
        • 6.3.3.2.2. By Deployment Model
        • 6.3.3.2.3. By End-User

7. Europe Generative AI in Personalized Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Personalized Medicine Therapeutics
    • 7.2.2. By Deployment Model
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Generative AI in Personalized Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Personalized Medicine Therapeutics
        • 7.3.1.2.2. By Deployment Model
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Generative AI in Personalized Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Personalized Medicine Therapeutics
        • 7.3.2.2.2. By Deployment Model
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Generative AI in Personalized Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Personalized Medicine Therapeutics
        • 7.3.3.2.2. By Deployment Model
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Generative AI in Personalized Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Personalized Medicine Therapeutics
        • 7.3.4.2.2. By Deployment Model
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Generative AI in Personalized Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Personalized Medicine Therapeutics
        • 7.3.5.2.2. By Deployment Model
        • 7.3.5.2.3. By End-User

8. Asia Pacific Generative AI in Personalized Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Personalized Medicine Therapeutics
    • 8.2.2. By Deployment Model
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Generative AI in Personalized Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Personalized Medicine Therapeutics
        • 8.3.1.2.2. By Deployment Model
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Generative AI in Personalized Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Personalized Medicine Therapeutics
        • 8.3.2.2.2. By Deployment Model
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Generative AI in Personalized Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Personalized Medicine Therapeutics
        • 8.3.3.2.2. By Deployment Model
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Generative AI in Personalized Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Personalized Medicine Therapeutics
        • 8.3.4.2.2. By Deployment Model
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Generative AI in Personalized Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Personalized Medicine Therapeutics
        • 8.3.5.2.2. By Deployment Model
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Generative AI in Personalized Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Personalized Medicine Therapeutics
    • 9.2.2. By Deployment Model
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Generative AI in Personalized Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Personalized Medicine Therapeutics
        • 9.3.1.2.2. By Deployment Model
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Generative AI in Personalized Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Personalized Medicine Therapeutics
        • 9.3.2.2.2. By Deployment Model
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Generative AI in Personalized Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Personalized Medicine Therapeutics
        • 9.3.3.2.2. By Deployment Model
        • 9.3.3.2.3. By End-User

10. South America Generative AI in Personalized Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Personalized Medicine Therapeutics
    • 10.2.2. By Deployment Model
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Generative AI in Personalized Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Personalized Medicine Therapeutics
        • 10.3.1.2.2. By Deployment Model
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Generative AI in Personalized Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Personalized Medicine Therapeutics
        • 10.3.2.2.2. By Deployment Model
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Generative AI in Personalized Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Personalized Medicine Therapeutics
        • 10.3.3.2.2. By Deployment Model
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Generative AI in Personalized Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Syntegra
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. NioyaTech
  • 15.3. Saxon
  • 15.4. IBM Watson
  • 15.5. Microsoft Corporation
  • 15.6. Google LLC
  • 15.7. Tencent Holdings Ltd.
  • 15.8. Neuralink Corporation
  • 15.9. Johnson & Johnson
  • 15.10. OpenAI
  • 15.11. Oracle

16. Strategic Recommendations

17. About Us & Disclaimer